Background: Masticatory myofascial trigger points (TrPs) represent a major contributor to non-dental orofacial pain. The primary treatment for myofascial TrPs involves intramuscular injections, which can be painful and anxiety-inducing for patients. An alternative, pain-free treatment approach for myofascial pain is iontophoresis.
Aim of this study: This study aimed to assess the efficacy of Botulinum toxin type A (BTX-A) Iontophoresis in managing muscle activity, Visual Analogue Scale (VAS) pain scores, mouth opening range, and Electromyography in individuals diagnosed with myofascial pain dysfunction syndrome (MPDS).
Materials and methods: Twenty-two patients exhibiting symptoms of MPDS in the masseter muscle were included. These patients were randomly divided into two equal groups: the study group (n=11) received BTX-A iontophoresis, while the control group (n=11) received saline iontophoresis as a placebo. Muscle activity at rest and during function was assessed using VAS, the range of mouth opening was measured, and electromyography assessments were conducted. These assessments were performed pre-operatively and during all follow-up visits.
Results: There analysis revealed no significant differences between the two groups at any of the measured timepoints (preoperative, immediate postoperative and 3-month follow-up) concerning pain levels, mouth opening or muscle activity.
Conclusion: The current study revealed no significant differences between the BTX-A and saline groups in the treatment of MPDS by iontophoresis.